Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



Carboplatin with or without Pembrolizumab in Treating Patients with Advanced Breast Cancer with Locally Recurrent Chest Wall Disease That Cannot Be Removed by Surgery

Breast

This randomized phase II trial studies how well carboplatin with or without pembrolizumab work in treating patients with breast cancer that has spread to other places in the body with chest wall disease that has come back and cannot be removed by surgery. Monoclonal antibodies, such as carboplatin and pembrolizumab, may interfere with the ability of tumor cells to grow and spread.
Breast
II
Abramson, Vandana
NCT03095352
VICCBRE1808

Phase II Umbrella Study of Novel Anti-cancer Agents in Patients With NSCLC Who Progressed on an Anti-PD-1 / PD-L1 Containing Therapy.

Multiple Cancer Types

This is an open-label, multi-centre, umbrella Phase II study in patients with metastatic NSCLC who have progressed on an anti-PD-1 / PD-L1 containing therapy. This study is modular in design, allowing initial assessment of the efficacy, safety, and tolerability of multiple treatment arms.
Lung, Non Small Cell
II
Horn, Leora
NCT03334617
VICCTHO1810

Nivolumab and Ipilimumab in Estimating Anti-Tumor Activity and Identifying Potential Predictors of Response in Patients with Melanoma That is Metastatic or Cannot Be Removed by Surgery

Melanoma

This phase II trial studies how well nivolumab and ipilimumab work in estimating anti-tumor activity and identifying potential predictors of response in patients with melanoma that is spreading to other places in the body or that cannot be removed by surgery. Monoclonal antibodies, such as nivolumab and ipilimumab, may interfere with the ability of tumor cells to grow and spread.
Melanoma
N/A
Johnson, Douglas
NCT02978443
VICCMEL1816

Iodine I-131 with or without Selumetinib in Treating Patients with Recurrent or Metastatic Thyroid Cancer

This randomized phase II trial studies how well iodine I-131 works with or without selumetinib in treating patients with thyroid cancer that has returned or has spread from where it started to other places in the body. Many thyroid cancers absorb iodine. Due to this, doctors often give radioactive iodine (iodine I-131) alone to treat thyroid cancer as part of standard practice. It is thought that the more thyroid tumors are able to absorb radioactive iodine, the more likely it is that the radioactive iodine will cause those tumors to shrink. Selumetinib may help radioactive iodine work better in patients whose tumors still absorb radioactive iodine. It is not yet known whether iodine I-131 is more effective with or without selumetinib in treating thyroid cancer.
Not Available
II
Bischoff, Lindsay
NCT02393690
VICCHN1817

WAPPS- Hemo (Web Accessible Population Pharmacokinetics Service - Hemophilia)
Protocol ? Phase 2: Testing and Validation

Not Available
II
Wheeler, Allison
NCT02061072
VICCNCBH1824

DS-8201a in Human Epidermal Growth Factor Receptor2 (HER2)-Expressing Colorectal Cancer

The main objective of this study is to test the safety and effectiveness of DS-8201a for participants with HER2-expressing advanced colorectal cancer.
Not Available
II
Ciombor, Kristen
NCT03384940
VICCGI1825

Safety Study of MGD006 in Relapsed / Refractory Acute Myeloid Leukemia (AML) or Intermediate-2 / High Risk MDS

The primary goal of this Phase 1 / 2, dose-escalation study, is to determine the maximum tolerated dose level of flotetuzumab in patients with AML whose disease is not expected to benefit from cytotoxic chemotherapy. Studies will also be done to see how the drug acts in the body (pharmacokinetics [PK], pharmacodynamics) and to evaluate potential anti-tumor activity of flotetuzumab.
Not Available
I/II
Moyo, Tamara
NCT02152956
VICCHEMP1828

A Study of Nivolumab Plus Brentuximab Vedotin Versus Brentuximab Vedotin Alone in Patients With Advanced Stage Classical Hodgkin Lymphoma, Who Are Relapsed / Refractory or Who Are Not Eligible for Autologous Stem Cell Transplant,

The purpose of this study is to determine whether an investigational immuno-therapy combination, nivolumab with Brentuximab vedotin compared to Brentuximab vedotin alone is safe and effective in the treatment of relapsed and refractory Classical Hodgkin Lymphoma. The participants of this trial will comprise of patients who have relapsed or did not respond to treatment and are not eligible for stem cell transplant
Not Available
III
Reddy, Nishitha
NCT03138499
VICCPCL1829

Alpha-1-Proteinase Inhibitor Human in Preventing Development of Steroid-Refractory Graft Versus Host Disease in Stem Cell Transplant Participants

This phase II trial studies the side effects and how well alpha-1-proteinase inhibitor human works in preventing development of graft versus host disease in stem cell transplant participants. Graft versus host disease is the most common serious complication after receiving a bone marrow transplant. Alpha-1-proteinase inhibitor human may help prevent the inflammatory immune response from graft versus host disease and damage to the skin, liver, stomach, and / or intestines.
Not Available
II
Kitko, Carrie
NCT03459040
VICCBMT1833

Optimization of Cancer Therapy Using Immune Effector Cells

Hematologic

Hematologic
N/A
Oluwole, Olalekan
VICCBMT1834

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: